News
15d
GlobalData on MSNGSK’s speciality medicines soar while generals drop, Q2 results reveal
UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its current portfolio. While the company’s total sales in this period totalled £8bn ...
1d
TipRanks on MSNGSK Expands Share Buyback Programme with New Purchase
GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...
2d
TipRanks on MSNGSK Executives Acquire Shares Under Reward Plan
GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK plc announced the acquisition of ordinary shares by several key executives under the ...
Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...
Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...
GSK Egypt posted non-consolidated net profits after tax of EGP 71.33 million in H1-25, an annual drop from EGP 99.54 million. Meanwhile, the EPS declined to EGP 0.85 from EGP 1.19. In April-June 2025, ...
LONDON—With its second-quarter report Wednesday, GlaxoSmithKline PLC GSK -1.52% has pivoted investors toward future expansion following its $20 billion asset swap with Novartis AG, saying it is ...
Jan 15 (Reuters) - GlaxoSmithKline (GSK.L) on Saturday said it had rejected a 50-billion-pound offer from Unilever (ULVR.L) for its consumer goods arm, saying it "fundamentally undervalued" the ...
GlaxoSmithKline PLC leaders and executives have shown their dedication by being a leading pharmaceutical company and research and development firm. GSK was named one of the 100 Best Companies for ...
After its own COVID-19 vaccine setback, GlaxoSmithKline has inked a $180 million deal to help German biotech company CureVac manufacture 100 million doses of its mRNA vaccine, which is currently ...
NurPhoto via Getty Images On April 27, 2022, GlaxoSmithKline GSK -2.9% plc (NYSE: GSK, $45.44, Market Capitalization: $115.5 billion) reported 1Q22 results.
Avandia: GlaxoSmithKline Cover-Up Turns Off Doctors GlaxoSmithKline withheld studies that made their drug Avandia, look unsafe. By ABC News July 13, 2010, 11:24 AM ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results